Join our Live Stream

The importance of CRP Point of Care testing in respiratory infections and in the fight against COVID-19 and Antimicrobial Resistance

4th September | 15:30 — 16:45 CET

CPD Accredited

Current Time 0:00
Duration Time 0:35
Loaded: 0%
Progress: 0%
Stream TypeLIVE
Remaining Time -0:35



    Prof. Nicholas Francis

    CRP Point of Care testing to reduce antibiotic prescribing in acutely exacerbated COPD patients


    Prof. Ivan Gentile

    Severity assessment and outcome prediction in the COVID-19 patients


    Dr. Carl Llor

    The emergence of multi-resistance associated with the overuse of antibiotics during COVID-19 pandemic


    Prof. Dag Berild

    Antimicrobial stewardship in the time of COVID-19 is vital — AMR still persists and could be height


    Dr. Aggy York

    Panel Discussion: CRP and Point of Care testing — knowledge sharing from across Europe

Register its Free


Join a panel of experts from across Europe for this compelling webinar presenting a view from the front line in Europe.

The webinar will analyse studies from around the world that show that C-reactive protein (CRP) levels proved to be one of the strongest inflammatory markers for severity and risk assessment in COVID-19 patients. [1] [2] [3] [4] [5]

The webinar will highlight the importance of Antibiotic Stewardship Programs (ASPs) in the context of the global pandemic and how antibiotics should be used only when necessary to curb the rise of antimicrobial resistance (AMR). [6] [7] [8] [9]

90% of respiratory tract infections (RTIs) are viral and therefore antibiotics have no clinical benefit. And yet RTIs are one of the most common reasons for unnecessary antibiotic prescribing. [10]

The webinar will also showcase the findings of a UK-based multicentre trial called the PACE study, which was published in 2019 in the New England Journal of Medicine and which recommended that CRP point-of-care testing can guide antibiotic therapy in acutely exacerbated chronic obstructive pulmonary disease (COPD). [10]

Learning Outcomes

  • Despite the viral origin of COVID-19, a standard reflex by physicians is to start treatment with antibiotics since cough, fever and radiologic infiltrates are hallmarks of bacterial community-acquired pneumonia, which requires antibiotic treatment. [9]
  • The detection of CRP is of certain value to distinguish whether there is a bacterial infection in the lung. [6]
  • CRP may reflect disease severity and may be an independent predictor of adverse outcomes in COVID-19 patients. [1] [2] [3] [4] [5]
  • Antibiotics should be reserved for the patients with the most severe presentations. [9]
  • Avoid blind or inappropriate use of antibacterial drugs, especially the combination of broad-spectrum antibacterial drugs. [6]
  • The use of CRP point-of-care testing in patients presenting with acute exacerbations of COPD in primary care resulted in a 20.4% absolute reduction of antibiotic prescribing. [11]
  • There are many reasons why European countries launch Antibiotic Stewardship Programs (ASPs), and in the context of COVID-19, an ASP is needed now more than ever.


Professional Blended Learning Continuum

  • MyPOCAcademy is an interactive educational resource providing information on the rationale for Point of Care Testing testing and its value, across a number of medical specialities.
  • The courses will allow you to enhance your knowledge and skills at your own pace.
  • CME-accredited materials and webinars will be available shortly

Assess Your Understanding

  • Within each course are test questions that allow you to test your knowledge.
  • Interactive patient case studies enable you to view the benefits of Point of Care Testing in real-life clinical scenarios

Convenient Access to Latest POC Information

  • MyPOCAcademy is your go-to resource for the latest information related to Point of Care Testing.
  • Learning can be accessed at your convenience with the click of a button.
Current Time 0:00
Duration Time 2:00
Loaded: 0%
Progress: 0%
Stream TypeLIVE
Remaining Time -2:00
  1. CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). April 3, 2020.
  2. Luo X, et al. medRxiv. Published online 2020.
  3. Tan C, et al. ORCID iD: 0000-0002-2522-4524.
  4. Wang L. Médecine et maladies infectieuses. 2020.
  5. Li H, et al. Journal of Infection. Published online 2020.
  6. Huttner B, et al. COVID-19: Don’t neglect antimicrobial stewardship: principles! Clinical Microbiology and Infection. 2020.
  7. Guan W, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20. doi:10.1056/NEJMoa2002032
  8. Rawson T, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;2:ciaa530. doi:10.1093/cid/ciaa530.32358954
  9. Jin YH, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research. 2020;7:4.
  10. Aabenhus R, et al. Cochrane Database of Systematic Reviews. 2014;11. Art. No.: CD010130.
  11. Butler CC, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. New Engl J Med. 2019;381(2):111-120